Our Pricing

Buy Semaglutide Injection UK - Order Online Today

Looking to buy semaglutide injection UK online with confidence? Cured Pharmacy offers genuine UK-licensed Wegovy (semaglutide) from £79.00, with transparent pricing shown before your free clinical consultation. Our UK-registered prescribers assess your suitability in under 3 minutes, ensuring safe, discreet access to this MHRA-approved weight loss treatment.

How Semaglutide Injections Work for Weight Loss

Semaglutide is a GLP-1 receptor agonist that mimics a natural hormone your gut produces after eating [1]. By activating GLP-1 receptors in the brain, pancreas, and digestive system, it reduces appetite, slows gastric emptying, and improves blood sugar regulation—mechanisms that collectively support significant weight reduction when combined with lifestyle changes.

The STEP clinical trial programme demonstrated semaglutide's efficacy across diverse patient populations. In STEP 1, participants using 2.4mg weekly semaglutide achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. These results led to the MHRA licensing Wegovy specifically for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [2].

Clinical experience shows semaglutide works best as part of a comprehensive approach. Patients typically report reduced food cravings within the first two weeks, though maximum weight loss generally occurs between months 4 and 12. Your UK prescriber will start you on a lower dose and gradually increase it over 16-20 weeks to minimise gastrointestinal side effects whilst optimising therapeutic response.

Semaglutide Injection Dosing and Administration

Wegovy is administered as a once-weekly subcutaneous injection, typically into the abdomen, thigh, or upper arm. Each pre-filled pen contains a single dose, making self-administration straightforward after initial training. The injection takes less than a minute and uses a fine needle that most patients find comfortable.

The standard dose escalation schedule begins at 0.25mg weekly for four weeks, increasing every four weeks through 0.5mg, 1mg, and 1.7mg, until reaching the maintenance dose of 2.4mg weekly [2]. This gradual titration significantly reduces the incidence of nausea and vomiting—the most common side effects reported in clinical trials. If you experience persistent side effects at any dose level, your prescriber may recommend staying at your current dose for an additional four weeks before escalating.

Most patients find a consistent injection day works best—many choose Sunday evenings or Monday mornings to establish routine. If you miss a dose and it's been less than five days, take it as soon as you remember. If more than five days have passed, skip that dose and resume your regular schedule. Never double up doses to compensate for a missed injection.

What to Expect During Treatment

During the first month on semaglutide, you may notice reduced hunger between meals and earlier satiety when eating. Some patients experience mild nausea, particularly in the first few weeks after each dose increase—this typically resolves as your body adjusts. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods can help manage these initial effects. Weight loss typically becomes noticeable from week 4 onwards, accelerating as you reach higher doses.

Wegovy vs Other Semaglutide Products

Semaglutide is available in the UK under different brand names, each licensed for specific indications. Wegovy contains semaglutide formulated specifically for weight management, with doses up to 2.4mg weekly. Ozempic, whilst containing the same active ingredient, is licensed exclusively for type 2 diabetes management at lower maximum doses (1mg weekly) [3].

The distinction matters clinically and legally. Wegovy's higher dosing delivers greater weight loss outcomes—the STEP trials used 2.4mg doses, whilst diabetes studies with Ozempic used 0.5mg to 1mg doses [1][3]. Prescribing Ozempic for weight loss constitutes off-label use, which UK prescribers may only consider when licensed alternatives are unsuitable or unavailable. At Cured Pharmacy, our clinical team prescribes Wegovy for weight management, ensuring you receive the appropriate formulation and dose for your treatment goals.

Both products require identical injection technique and weekly administration. The pre-filled pens use the same design, and side effect profiles are comparable at equivalent doses. Your prescriber will determine which semaglutide product suits your medical history and treatment objectives.

Comparing GLP-1 Weight Loss Treatments

Beyond semaglutide, other GLP-1 receptor agonists are available for weight management in the UK. Saxenda (liraglutide) requires daily injections at a maximum 3mg dose, whilst Mounjaro (tirzepatide) is a dual GIP/GLP-1 agonist administered weekly. Head-to-head trials suggest tirzepatide may produce slightly greater weight loss than semaglutide, though both significantly outperform older treatments like orlistat [4]. Your prescriber will discuss which option aligns with your preferences, medical history, and budget.

Buy Semaglutide Injection UK: What You Need to Know

Semaglutide is a prescription-only medication in the UK, meaning you cannot legally purchase it without a valid prescription from a UK-registered prescriber. At Cured Pharmacy, we've streamlined this process: complete a brief online consultation reviewed by our clinical team, typically within hours. If approved, your prescription is sent to our GPhC-registered pharmacy (9012511) for dispensing and discreet delivery to your home.

Transparent pricing sets Cured Pharmacy apart. You'll see the exact cost—from £79.00 for Wegovy—before starting your consultation, with no hidden fees added at checkout. This upfront approach means you can make informed decisions about your treatment without unexpected costs. Our lowest price guarantee ensures you're getting competitive UK pricing without compromising on pharmaceutical standards or clinical oversight.

Beware of websites offering semaglutide without a prescription or clinical assessment. These sources often supply counterfeit or improperly stored medications that may be ineffective or dangerous. The MHRA regularly issues warnings about fake weight loss injections entering the UK market [5]. Purchasing from a registered UK pharmacy like Cured ensures you receive genuine, refrigerated medications with full regulatory compliance and ongoing prescriber support.

Semaglutide Side Effects and Safety Considerations

The most frequently reported side effects of semaglutide are gastrointestinal: nausea (44% of patients in STEP 1), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These effects are usually mild to moderate, occurring primarily during dose escalation, and diminishing over time. Eating smaller, more frequent meals and avoiding fatty or spicy foods can help manage symptoms.

Less common but more serious risks include pancreatitis, gallbladder disease, and hypoglycaemia (particularly if you're taking other diabetes medications). Semaglutide carries a boxed warning in the US regarding thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans [2]. As a precaution, semaglutide should not be used if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Your online consultation at Cured Pharmacy screens for contraindications including pregnancy, breastfeeding, type 1 diabetes, diabetic ketoacidosis, severe gastrointestinal disease, and previous pancreatitis. Our prescribers, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), review your medical history to ensure semaglutide is safe and appropriate for you. If approved, you'll receive detailed patient information covering side effects, warning signs, and when to seek medical attention.

When to Contact Your Prescriber

Seek immediate medical attention if you experience severe abdominal pain that doesn't resolve, persistent vomiting, signs of pancreatitis (upper abdominal pain radiating to your back), or symptoms of gallbladder problems (yellowing skin or eyes, fever with abdominal pain). Contact your prescriber if side effects persist beyond the first few weeks of a new dose or if you're unable to tolerate the medication. Most patients successfully complete dose escalation, but individual adjustments may be necessary.

Maximising Results with Semaglutide Treatment

Clinical trials demonstrate that semaglutide produces optimal results when combined with a reduced-calorie diet and increased physical activity [1]. Whilst the medication significantly reduces appetite, conscious nutritional choices amplify weight loss and improve metabolic health markers. Focus on protein-rich foods to preserve lean muscle mass, prioritise vegetables and whole grains for satiety and nutrients, and stay well-hydrated throughout the day.

Regular physical activity enhances semaglutide's effects and provides independent cardiovascular and metabolic benefits. NICE guidelines recommend at least 150 minutes of moderate-intensity activity weekly for weight management [6]. Many patients find starting with achievable goals—such as daily 20-minute walks—builds sustainable habits. As weight decreases and energy improves, you can gradually increase exercise intensity and duration.

Long-term success requires viewing semaglutide as part of ongoing weight management rather than a temporary solution. Clinical data shows most weight regain occurs after discontinuing treatment, suggesting many patients benefit from continued therapy [7]. Your prescriber will discuss appropriate treatment duration based on your response, weight loss goals, and overall health. Regular follow-up consultations at Cured Pharmacy ensure your treatment remains effective and safe as your needs evolve.

Monitoring Your Progress

Track your weight weekly at the same time of day, ideally first thing in the morning. Beyond the scales, monitor non-scale victories: improved energy levels, better-fitting clothes, enhanced mobility, and positive changes in blood pressure or blood sugar if you have comorbidities. Take progress photos monthly—visual changes often become apparent before dramatic scale movements. Share this information during follow-up consultations to help your prescriber optimise your treatment plan.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Medicines and Healthcare products Regulatory Agency. (2022). Wegovy 2.4mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. https://products.mhra.gov.uk/
3. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
5. Medicines and Healthcare products Regulatory Agency. (2023). Fake weight-loss medicines: MHRA warning about unlicensed and counterfeit products. MHRA Drug Safety Update. https://www.gov.uk/drug-safety-update
6. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (Clinical guideline CG189). NICE. https://www.nice.org.uk/guidance/cg189
7. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.